arrow
H

Harish Bhujade

Postgraduate Institute of Medical Education and Research
H指数:12
被引数:547

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Expanding The Scope of Endohepatology: A Single Center Experience of Endoscopic Ultrasound guided Locoregional Therapies for Hepatocellular Carcinoma [With Video]

拓展内镜肝病学范围:单中心关于内镜超声引导下局部区域治疗肝细胞癌的经验[附视频]

2026-10-190
PRE
Effect of Blood Group on von Willebrand Factor Antigen Levels in Compensated Advanced Chronic Liver Disease and Utility of von Willebrand Factor- Platelet Ratio for Detecting Clinically Significant Portal Hypertension

血型对代偿期晚期慢性肝病中血管性血友病因子抗原水平的影响及血管性血友病因子-血小板比值在检测临床显著门静脉高压中的价值

2026-08-240
PRE
Incidence, Predictors, and Course of Hepatocellular Carcinoma Following Direct-Acting Antivirals Therapy in a Prospective Genotype-3 Predominant HCV Elimination Compensated Cirrhosis Cohort

直接抗病毒药物治疗后,在前瞻性基因型-3为主的HCV清除性代偿期肝硬化队列中,肝细胞癌的发生率、预测因子和病程

2026-08-010
PRE
Noncontrast abbreviated MRI demonstrates superior diagnostic accuracy compared to ultrasound for hepatocellular carcinoma detection: Interim results from a prospective surveillance trial

无对比剂缩短版MRI在肝细胞癌检测中显示出比超声更高的诊断准确性:前瞻性监测试验的初步结果

2026-05-012
PRE
Point-of-care ultrasound (POCUS) guided pragmatic fluid and albumin resuscitation and hemodynamic monitoring in Cirrhosis and Septic Shock
2026-01-090
PRE
Point-of-care ultrasound (POCUS)-guided volume management and the effect of cirrhotic cardiomyopathy on acute kidney injury outcomes in cirrhosis

床旁超声(POCUS)指导下的容量管理以及肝硬化性心肌病对肝硬化急性肾损伤预后的影响

2025-09-011
PRE
Nonsuperiority of Simultaneous Compared With Sequential Interventions in Infected Necrotic Collections at Multiple Sites in Acute Necrotizing Pancreatitis: A Randomized Trial

与序贯干预相比,同时干预在急性坏死性胰腺炎多部位感染性坏死积液中的非优越性:一项随机试验

2025-07-240
PRE
Experience With Dabigatran on Rate of Portal Vein Thrombosis Recanalization, Disease Progression and Survival

达比加群对门静脉血栓再通率、疾病进展和生存率的影响

2025-01-031
PRE
Recompensation of Chronic Hepatitis C-Related Decompensated Cirrhosis Following Direct-Acting Antiviral Therapy: Prospective Cohort Study From a Hepatitis C Virus Elimination Program
2024-12-011
PRE